Linzagolix CAS 935283-04-8

Product Description:

Product Name: linzagolix CAS NO: 935283-04-8

Synonyms:

5-Carboxy-3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny l]thieno[3,4-d]pyrimidine-2,4(1H,3H)-dione;

Chemical & Physical Properties:

Appearance: Solid powder

Assay: ≥98.0%

Density: 1.6±0.1 g/cm3

Storage Condition: Dry, dark and at 0 – 4℃ for short term (days to weeks) or -20℃ for long term (months to years).

Solubility: Soluble in DMSO

An orally bioavailable gonadotropin-releasing hormone (GnRH or LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration of linzagolix, this agent competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosteron e. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer. In women, this prevents the production of estroge n by the ovaries and may relieve symptoms from sex-hormone dependent diseases, such as pain associated with endometriosis, heavy menstrual bleeding or uterine fibroids.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.